non-metastatic CRPC

November 28, 2018

European Advisory Committee Recommends Approval of Erleada for Men at Risk of Prostate Cancer Spreading

News

Janssen‘s hormone therapy Erleada (apalutamide) may soon be used in Europe for men with castration-resistant prostate cancer (CRPC) who have a high risk of their disease spreading, after the Committee for Medicinal ... Read more

July 5, 2018July 10, 2018

Xtandi May Not Improve Overall Survival in Specific Type of Prostate Cancer, Early Phase 3 Data Suggest

News

Treatment with Xtandi (enzalutamide) does not seem to improve overall survival in men with non-metastatic castration-resistant prostate cancer (CRPC), according to the first interim analysis of a Phase 3 clinical trial. These findings were published in ... Read more

January 2, 2018January 2, 2018

FDA Grants Janssen Biotech’s Apalutamide Priority Review Designation to Treat Non-metastatic CRPC

News

The U.S. Food and Drug Administration (FDA) has granted priority review status to apalutamide — an investigational androgen receptor inhibitor — to treat men with non-metastatic castration-resistant prostate cancer (CRPC). This ... Read more